AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

11.36

+0.08 (0.71%)

At close: Sep 2, 2026, 4:00 PM EDT

11.35

-0.01 (-0.09%)

Pre-market: Sep 3, 2026, 5:01 AM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research Fees Revenue	28.53M	27.21M	26.28M
Milestone Payments Revenue	-	1.00M	1.50M
Licensing and Royalty Revenue	36.65M	46.92M	1.05M
Revenue (Other)	1.00M	-	-
Revenue (Total)	66.17M	75.13M	28.83M

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
In the Clinic - Partner-Led Programs with Downstreams	3.00	5.00	-
Preclinical Development - Partner-Led Programs with Downstreams	32.00	39.00	-
Total Partner-Led Programs with Downstreams	35.00	44.00	-
Molecules in the Clinic with Downstreams	12.00	14.00	-
Cummulative Number of Partner-Initiated Program Starts with Downstreams	-	104.00	96.00
Partner-Led - Cummulative Number of Molecules In the Clinic	-	17.00	-
AbCellera-Led - Cummulative Number of Molecules In the Clinic	-	2.00	-
Total Cummulative Number of Molecules In the Clinic	-	19.00	16.00